Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Why invest in GDR?
Genedrive PLC: THE INVESTMENT CASE
INVESTMENT OVERVIEW

Genedrive on track to commercialise its diagnostic products

Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India
Laboratory
INVESTMENT OVERVIEW: GDR The Big Picture
Genedrive has distribution agreements in place with two sizeable players

In the first half of 2018 Genedrive PLC (LON:GDR) was busy expanding into new markets and developing new projects.

The AIM-listed medical diagnostic group’s Hepatitis C Virus (HCV) ID kit is rapidly becoming available in target countries.  

HCV ID Kit expanding into new regions

Genedrive offers a rapid, low-cost, simple-to-use device with high sensitivity and specificity in testing for hepatitis C, analysts at Hardman & Co said.

“The hepatitis C market is a global opportunity, very large even in developing countries,“ the research house added.

Back in September, the HCV ID kit was awarded an CE IVD Certification, which allows for the kit to be sold in Europe,  as well as low- and middle-income countries that accept CE certification under their national regulations.

Genedrive has signed sales agreement with Sysmex Corporation for the distribution of the HCV ID to EMEA and Asia Pacific and with Mumbai- based ARKRAY to distribute the kit in India.

Sysmex, a Japanese Corporation, is a world leader in clinical systems.

"Now that the Genedrive technology platform has received CE Mark, the new management team has completely re-focused the company onto the commercialisation pathway for diagnosis of infectious diseases, signing two important commercial agreements with Sysmex, a major global player," Hardman & Co said.

Awards for NHS point-of care and tuberculosis testing kits

Genedrive also received a grant from the UK national Institute for Health Research’s Invention for Innovation programme for a NHS point-of-care test.

This pharmacogenetic test helps to avoid antibiotic-related hearing loss in new born children.

“The NHS is a huge market place and, if adopted, this would be the first placement of Genedrive in a developed world healthcare setting," said David Budd, chief executive.

The company has also been awarded £1.1mln in funding by Innovate UK for product development of its Genedrive tuberculosis testing kit.

The grant will be used for the further development of a high-sensitivity bacterial sample preparation module for the Genedrive instrument.

Financial Update

Group revenue for the six months to end December eased to £2.63mln from £2.88mln the year before.

Income derived from the flagship Genedrive device rose 8% to £1.3mln.

At the end of February, this had subsided to £3.9mln though last month the group completed the sale of the research and pharmacogenomics divisions for up to  £1.9mln in cash.

At 36.50p, Genedrive is valued at £8.8mln.

View full GDR profile View Profile

Genedrive PLC Timeline

Related Articles

Dog skeleton with cannabis plant leaf
July 17 2018
The company's lead drug candidate is a cannabis-derived canine pain medication.
blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use